Abstract: Disclosed is a preparation method of titanium catalyst for olefin polymerization, the method comprising (1) preparing magnesium compound solution by resolving non-deoxidative magnesium halide and IIIA group atom compound in a solvent mixture of cyclic ether, at least one alcohol, phosphorus compound and organosilane with or without hydrocarbon solvent; (2) reacting said magnesium compound solution with titanium compound, silicon compound, tin compound or mixture thereof to produce a support; and (3) reacting said support with titanium compound and electron donor to produce solid complex titanium catalyst, wherein the particle size and particle size distribution f said catalyst are regulated by controlling solubility of the reactants in said steps (2) and/or (3).

Abstract: Disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof.

Abstract: Provided is a biocompatible device which has been coated or sealed with a polyether or polyether/carbonate based urethane polymer that contains functional groups (e.g. carboxylic acid groups) which are capable of serving as anchor sites for protein binding.

Abstract: The present invention relates to a receptor binding conjugate which consists of an antibody, a radionuclide and folate or a folate derivative, wherein or not the conjugate possesses dual binding ability. The present invention also relates to a method and a kit to prepare, as well as a method to use, such conjugates. Furthermore, the use of a conjugate according to the present invention to prepare a pharmaceutical solution is disclosed.

Abstract: A method of determining whether an individual has Attention Deficit Hyperactivity Disorder comprising: sampling the eye movement of a human subject during a predetermined time interval when the subject is in an inactive state to provide sampled eye movement data; and analyzing the sampled eye movement data for a pre-selected parameter, to determine whether said pre-selected parameter has a value indicative of ADHD.

Abstract: The invention features a control system for controlling the supply of bodyfeed to a filter for removing solids from a beer stream is described. By applying the bodyfeed at an appropriate rate and hence achieving appropriate effective bed voidage it is possible to maintain beer clarity while minimizing filter aid usage. The control system includes a means for determining turbidity of the liquid stream upstream of the filter, a means for determining the rate of pressure drop change across the filter, and a controller for altering the supply of bodyfeed to the filter in accordance with a calculated dose change.

Abstract: This invention provides a method for synthesizing ethyleneimine dimer which includes reacting 2-(2-aminoethylamino)ethanol with an aqueous HX solution to produce N-(2-haloethyl)-1,2-ethanediamine dihydrohalide; reacting this product with a base in a solvent to convert the N-(2-haloethyl)-1,2-ethanediamine dihydrohalide into ethyleneimine dimer; and purifying the dimer from the solvent. This method of synthesis provides several advantages over previous methods: (1) The starting compounds are all relatively inexpensive; (2) the yield of the product is greater than 20% of the theoretical yield; and (3) the steps of the synthesis are easy, inexpensive and amenable to large-scale production. All of these advantages allow for less expensive production of ethyleneimine dimer.

Abstract: A rodent epithelioid cell transformed with a recombinant DNA vector including a DNA sequence encoding human erythropoietin, the transformed cell being capable of producing N-linked and O-linked glycosylated human erythropoietin.

Abstract: Biologically active heterodimeric human FSH composed of an alpha subunit and a beta subunit, each subunit being synthesized by a cell having an expression vector containing heterologous DNA encoding the subunit.

Abstract: A method of extracting nucleic acids from a crude buffy coat fraction in an aqueous medium includes the steps of treating the buffy coat fraction to break open the white blood cells to release the proteins and the nucleic acids in the cells into the aqueous medium; solubilizing the proteins and the nucleic acids in the aqueous medium; and precipitating the nucleic acids under conditions under which the proteins remain in solution.

Abstract: Healing an external wound or regenerating bone of a mammal by administering to the mammal a composition containing purified platelet-derived growth factor and purified transforming growth factor alpha.

Abstract: Heptapeptide analogs of somatastatin which inhibit secretion of growth hormone.

Abstract: A decapeptide of the formula:N-Ac-A.sup.1 -A.sup.2 -A.sup.3 -Ser-A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -A.sup.9, wherein each A.sup.1, A.sup.2, and A.sup.3, independently, is D-.beta.-Nal, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, or C.sub.1-3 alkyl), D-Trp, D-benzothienyl (2)-Ala, or D-benzothienyl (1)-Ala; A.sup.4 is p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, or C.sub.1-3 alkyl), Tyr, Lys, Arg, Leu, Trp, or Nal; A.sup.5 is D-Lys, D-Tyr, D-Arg, D-Phe, D-.beta.-Nal, D-Trp, D-homo-Arg, D-diethyl-homo-Arg, D-p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, or C.sub.1-3 alkyl), or D-Lys-.epsilon.-NH-R (where R is H, a branched or straight chain C.sub.1 -C.sub.10 alkyl group, or an aryl group); A.sub.6 is Leu, .beta.-Nal, p-X-Phe (where X is halogen, H, NH.sub.2, NO.sub.2, OH, C.sub.2 F.sub.5, C.sub.1-3 alkyl), or Trp; A.sup.7 is Arg, Lys, or Lys .epsilon.-NH-R (where R is H, a branched or straight chain C.sub.1 -C.sub.6 alkyl group, or an aryl group); A.sub.8 is Pro; and A.sup.

Abstract: Healing an external wound or regenerating bone of a mammal by administering to the mammal a composition containing purified platelet-derived growth factor and purified insulin-like growth factor.

Abstract: A transgenic non-human eukaryotic animal whose germ cells and somatic cells contain an activated oncogene sequence introduced into the animal, or an ancestor of the animal, at an embryonic stage.